Post-marketing surveillance of adverse reactions to new medicines.
作者信息
Wilson A B
出版信息
Br Med J. 1977 Oct 15;2(6093):1001-3. doi: 10.1136/bmj.2.6093.1001.
Abstract
摘要
相似文献
1
Post-marketing surveillance of adverse reactions to new medicines.新药不良反应的上市后监测
Br Med J. 1977 Oct 15;2(6093):1001-3. doi: 10.1136/bmj.2.6093.1001.
2
Monitoring adverse reactions to drugs.监测药物不良反应。
Br Med J. 1977 Jan 8;1(6053):96-7. doi: 10.1136/bmj.1.6053.96.
3
New strategies for drug monitoring.药物监测的新策略。
Br Med J. 1977 Apr 2;1(6065):861-2.
4
Control and distribution of medicines in the future.未来药品的管控与分发
R Soc Health J. 1971 Sep-Oct;91(5):222-4. doi: 10.1177/146642407109100505.
5
Post-marketing surveillance.
Triangle. 1980;19(3-4):107-11.
6
Post-marketing surveillance in the UK (1984).英国的上市后监测（1984年）。
Br J Clin Pharmacol. 1986;22 Suppl 1(Suppl 1):71S-75S. doi: 10.1111/j.1365-2125.1986.tb02986.x.
7
Monitoring of drugs after marketing.药品上市后监测
J R Coll Gen Pract. 1983 Jul;33(252):438-41.
8
The safety of new drugs.
Br J Anaesth. 1989 Jun;62(6):587-9. doi: 10.1093/bja/62.6.587.
9
Post-marketing surveillance of licensed medicinal and other products.
Health Bull (Edinb). 1981 Nov;39(6):356-66.
10
European Medicines Agency assesses safety reporting at Roche.欧洲药品管理局评估罗氏公司的安全报告。
Lancet Oncol. 2012 Aug;13(8):e331. doi: 10.1016/s1470-2045(12)70297-8.
引用本文的文献
1
The past, present and perhaps future of pharmacovigilance: homage to Folke Sjoqvist.药物警戒的过去、现在和未来：向 Folke Sjoqvist 致敬。
Eur J Clin Pharmacol. 2013 May;69 Suppl 1:33-41. doi: 10.1007/s00228-013-1486-8. Epub 2013 May 3.
2
Patient reporting of potential adverse drug reactions: a methodological study.患者对潜在药物不良反应的报告：一项方法学研究。
Br J Clin Pharmacol. 2002 Mar;53(3):318-25. doi: 10.1046/j.0306-5251.2001.01547.x.
3
Acute intoxication and illness due to mild analgesics.轻度镇痛药所致的急性中毒与疾病
Br J Clin Pharmacol. 1980 Oct;10 Suppl 2(Suppl 2):381S-384S. doi: 10.1111/j.1365-2125.1980.tb01826.x.
4
[Drug safety: activities of the manufacturer].
Soz Praventivmed. 1980 Mar;25(1-2):14-7. doi: 10.1007/BF02075063.
5
Postmarketing surveillance: practical experience with ketotifen.上市后监测：酮替芬的实际应用经验
Br Med J (Clin Res Ed). 1984 Mar 24;288(6421):911-4. doi: 10.1136/bmj.288.6421.911.
6
Postmarketing surveillance of adverse reactions to drugs.药品不良反应的上市后监测。
Br Med J (Clin Res Ed). 1984 Mar 24;288(6421):879-80. doi: 10.1136/bmj.288.6421.879.
7
Postmarketing surveillance of the safety of cimetidine: 12 month mortality report.西咪替丁安全性的上市后监测：12个月死亡率报告。
Br Med J (Clin Res Ed). 1983 May 28;286(6379):1713-6. doi: 10.1136/bmj.286.6379.1713.
8
Identification of adverse reactions to new drugs. I: What have been the important adverse reactions since thalidomide?新药不良反应的识别。I：自沙利度胺事件以来有哪些重要的不良反应？
Br Med J (Clin Res Ed). 1983 Jan 15;286(6360):199-202. doi: 10.1136/bmj.286.6360.199.
9
Post-marketing surveillance in the UK (1984).英国的上市后监测（1984年）。
Br J Clin Pharmacol. 1986;22 Suppl 1(Suppl 1):71S-75S. doi: 10.1111/j.1365-2125.1986.tb02986.x.
10
Post marketing surveillance of captopril (for hypertension): a preliminary report.卡托普利（用于治疗高血压）的上市后监测：初步报告。
Br J Clin Pharmacol. 1987 Sep;24(3):343-9. doi: 10.1111/j.1365-2125.1987.tb03179.x.
本文引用的文献
1
Sclerosing peritonitis, an unusual reaction to a beta-adrenergic-blocking drug (practolol).硬化性腹膜炎，一种对β-肾上腺素能阻滞剂（心得宁）的罕见反应。
Lancet. 1974 Dec 21;2(7895):1477-81. doi: 10.1016/s0140-6736(74)90218-9.
2
Use of medicines in general practice.全科医疗中的药物使用
Br Med J. 1977 Jun 18;1(6076):1561-3. doi: 10.1136/bmj.1.6076.1561.
3
Drug monitoring and adverse reactions.药物监测与不良反应
Br Med J. 1977 Jun 4;1(6074):1467. doi: 10.1136/bmj.1.6074.1467.
4
Monitoring adverse reactions to new drugs: "restricted release" or "monitored release"?监测新药的不良反应：“限制发布”还是“监测发布”？
Br Med J. 1977 Mar 12;1(6062):691-2. doi: 10.1136/bmj.1.6062.691.
5
The discovery of drug-induced illness.
N Engl J Med. 1977 Mar 3;296(9):481-5. doi: 10.1056/NEJM197703032960904.
Zotero 插件